CN115337347B - Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease Download PDFInfo
- Publication number
- CN115337347B CN115337347B CN202210933894.4A CN202210933894A CN115337347B CN 115337347 B CN115337347 B CN 115337347B CN 202210933894 A CN202210933894 A CN 202210933894A CN 115337347 B CN115337347 B CN 115337347B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- honeysuckle
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 20
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 59
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 56
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 56
- 239000002994 raw material Substances 0.000 claims abstract description 52
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 43
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 43
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 36
- 235000011477 liquorice Nutrition 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 24
- 235000005412 red sage Nutrition 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims description 158
- 241000382455 Angelica sinensis Species 0.000 claims description 53
- 240000001341 Reynoutria japonica Species 0.000 claims description 51
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 229940069445 licorice extract Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 11
- 239000000469 ethanolic extract Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract description 7
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract description 7
- 244000081426 Ranunculus ficaria Species 0.000 abstract description 5
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract description 5
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 239000002245 particle Substances 0.000 description 25
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 18
- 210000004204 blood vessel Anatomy 0.000 description 16
- 206010008479 Chest Pain Diseases 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 238000009825 accumulation Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 206010007247 Carbuncle Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000002791 soaking Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 244000061520 Angelica archangelica Species 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000405414 Rehmannia Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 229960001317 isoprenaline Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application aims to provide an application of a traditional Chinese medicine composition in preparing a medicine for treating coronary heart disease, wherein the traditional Chinese medicine composition comprises the following raw material medicines: honeysuckle, figwort root, chinese angelica, liquorice, weeping forsythiae capsule, cassia twig, giant knotweed and red sage root.
Description
Technical Field
The application relates to a new application of a traditional Chinese medicine composition, in particular to an application of a traditional Chinese medicine composition for treating heat-accumulation blood vessels in preparing a medicine for treating coronary heart disease, and belongs to the field of traditional Chinese medicines.
Background
The "treatment based on syndrome differentiation" is a major feature of the clinical theory of TCM that is different from other medical systems. The development of new traditional Chinese medicine has close relation with the theory of the symptoms of traditional Chinese medicine. At present, the clinical research of Chinese patent medicines mostly adopts a mode of 'disease combination', namely, on the premise of definite disease diagnosis, the new medicine function is combined for mainly treating, and the adaptation syndrome is selected, which is a clinical research mode by referring to chemical medicines, and has certain limitation. The traditional Chinese medicine treatment emphasizes the "treatment based on syndrome differentiation", and the recipe is firstly aimed at the syndrome. Taking the six ingredients with rehmannia pill as an example, if the six ingredients with rehmannia pill is studied by simply using the mode of 'disease combination', the main treatment scope of the six ingredients with rehmannia pill can be limited by the kidney yin deficiency syndrome of a specific disease, the extension of the main treatment scope can not be expanded, the treatment scope of the six ingredients with rehmannia pill can not be fully developed, and the differentiation concept and the Chinese medicine characteristics of the Chinese medicine can not be fully reflected.
Based on this, the concept of "new traditional Chinese medicine of syndrome type" is proposed, and "new traditional Chinese medicine of syndrome type" is mainly used as a new traditional Chinese medicine of syndrome type, which is different from the traditional Chinese medicine mainly used as a certain syndrome type of disease, and has the research significance of exploring a new research and development mode of traditional Chinese medicine which takes syndrome as the center, accords with the diagnosis and treatment mode of traditional Chinese medicine and can embody the characteristics of traditional Chinese medicine. The medicine is different from a traditional Chinese medicine compound preparation mainly used for combining symptoms and signs, the disease concept of modern medicine is set aside, and the research and development of the medicine are certainly beneficial to developing the traditional characteristics of the traditional Chinese medicine. The syndrome type Chinese medicine takes syndrome as an intervention object, and based on the diagnosis and treatment theory, treats different diseases simultaneously, embodies the integral concept of traditional Chinese medicine, is beneficial to evaluating the advantages and characteristics of traditional Chinese medicine, and is focused by a plurality of expert students at the beginning of research and development. The Chinese patent medicine "Liuwei Dihuang pill" is a typical representative of the medicines, the application range of the pill gets rid of the constraint of modern diseases, and since the pill is marketed, the pill is popular with the masses due to the characteristics of simple and convenient operation and wide application range, and the health service capability of the Chinese medicine is greatly improved. Therefore, the research and development of the medicines tend to further promote the development of traditional Chinese medicine industry.
Heat accumulation in blood vessels means that physical matters such as heat evil and blood stasis are difficult to resolve in blood vessels, cause and result in poor circulation process of accumulated heat, toxic materials generation, accumulation of mass and damage of vessels. The main pathogenesis is that heat evil and physical matters such as blood stasis, phlegm dampness and the like in blood vessels mutually beat and tie, and the disease is located in the blood vessels. First, it is a "hot" problem. The intangible "heat" is mainly derived from two sources, one of which is the invasion of exogenous pathogenic qi into the interior to transform heat. As Liu Wansu emphasizes, six qi can transform heat into fire. Different ways of pathogenic qi transforming into heat are closely related to the physical state of the body and the characteristics of the pathogenic factors. The pathological products in the blood vessels can stagnate and transform heat. For instance, it can remove fire and generate heat in blood vessels, such as phlegm-dampness and blood stasis. In addition, heat may also be caused by excessive yin and yang and excessive five-element polarized fire. Second, the "node" is the key pathogenesis. In the Shang Han Lun examination syndrome, "what is the case of the combination of pathogenic factors and things? Blood is also water. The physical matters of the intangible pathogenic factors and the water blood are mutually paced as knots. Here, both the intangible pathogenic qi and the tangible substance "water blood" are indispensable. Third, the disease is in the "blood vessel". Blood vessels are extraordinary hollow, are connected with heart and lung, are distributed throughout the body and are channels for qi and blood, and are characterized by storing essence and qi without diarrhea, so that the relative constancy of blood volume and quality can be maintained.
Disclosure of Invention
The application aims to provide a traditional Chinese medicine composition aiming at the traditional Chinese medicine syndrome of heat-accumulation blood vessel, and the traditional Chinese medicine composition provides a new treatment thought and means for clinical treatment of hypertension and coronary heart disease.
As one aspect of the application, the application provides a traditional Chinese medicine composition for treating heat-accumulation blood vessels, which comprises the following raw material medicines: honeysuckle, figwort root, chinese angelica, liquorice, weeping forsythiae capsule, cassia twig, giant knotweed and red sage root.
Preferably, the traditional Chinese medicine composition comprises the following raw materials: 5-30 parts of honeysuckle, 5-30 parts of radix scrophulariae, 3-18 parts of angelica sinensis, 3-18 parts of liquorice, 5-30 parts of fructus forsythiae, 5-30 parts of cassia twig, 3-18 parts of polygonum cuspidatum and 5-30 parts of radix salviae miltiorrhizae.
Further preferably, the raw materials of the traditional Chinese medicine composition are as follows: 9-24 parts of honeysuckle, 9-24 parts of radix scrophulariae, 5-15 parts of angelica sinensis, 5-15 parts of liquorice, 9-24 parts of fructus forsythiae, 9-24 parts of cassia twig, 5-15 parts of polygonum cuspidatum and 9-24 parts of radix salviae miltiorrhizae.
Still more preferably, the raw materials of the traditional Chinese medicine composition are: 12-18 parts of honeysuckle, 12-18 parts of radix scrophulariae, 7-12 parts of angelica sinensis, 7-12 parts of liquorice, 12-18 parts of fructus forsythiae, 12-18 parts of cassia twig, 7-12 parts of polygonum cuspidatum and 12-18 parts of radix salviae miltiorrhizae.
Most preferably, the traditional Chinese medicine composition comprises the following raw materials: 15 parts of honeysuckle, 15 parts of radix scrophulariae, 9 parts of angelica sinensis, 9 parts of liquorice, 15 parts of fructus forsythiae, 15 parts of cassia twig, 9 parts of polygonum cuspidatum and 15 parts of radix salviae miltiorrhizae;
or 13 parts of honeysuckle, 17 parts of radix scrophulariae, 8 parts of angelica sinensis, 11 parts of liquorice, 13 parts of fructus forsythiae, 17 parts of cassia twig, 8 parts of polygonum cuspidatum and 16 parts of radix salviae miltiorrhizae;
or 17 parts of honeysuckle, 13 parts of radix scrophulariae, 11 parts of angelica sinensis, 8 parts of liquorice, 17 parts of fructus forsythiae, 13 parts of cassia twig, 11 parts of polygonum cuspidatum and 13 parts of radix salviae miltiorrhizae.
In the above technical scheme, the traditional Chinese medicine composition can be any form formed by or prepared from the above raw materials, and comprises the following components: the raw materials are respectively crushed and then mixed to form a composition; or the composition is obtained by mixing the raw materials and crushing the mixture; or mixing the above raw materials, extracting by conventional extraction method to obtain extract, purifying to obtain effective components, and preparing into conventional oral dosage form by conventional preparation process.
The conventional extraction method comprises soaking extraction, decocting extraction, reflux extraction, percolation extraction, ultrasonic extraction, microwave extraction, etc.; the extraction solvent comprises water or conventional organic solvents such as ethanol, methanol, ethyl acetate, petroleum ether, isopropanol, etc.; the refining and purifying process comprises extraction, column chromatography separation, high performance liquid chromatography separation and the like.
The conventional oral dosage forms comprise tablets, capsules, granules, pills, powder and oral liquid. The preparation of the dosage form requires the addition of common pharmaceutically acceptable auxiliary materials, including: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrices, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, and the like; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, crosslinked sodium carboxymethyl cellulose, and the like; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the binder includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.
The traditional Chinese medicine composition can be added in the form of raw materials, and can also be added in the form of an extract or prepared into particles. Therefore, as another aspect of the present application, the present application further provides a traditional Chinese medicine composition for treating heat-induced blood vessels, which comprises the following raw materials: honeysuckle extract, radix scrophulariae extract, angelica extract, licorice extract, fructus forsythiae extract, cassia twig extract, polygonum cuspidatum extract and red sage root extract; wherein the extract is water extract or ethanol extract of each raw material medicine respectively, or is granule prepared by the extract according to the conventional process.
Preferably, the traditional Chinese medicine composition comprises the following raw materials: 5-30 parts of honeysuckle extract, 5-30 parts of radix scrophulariae extract, 3-18 parts of Chinese angelica extract, 3-18 parts of licorice extract, 5-30 parts of fructus forsythiae extract, 5-30 parts of cassia twig extract, 3-18 parts of polygonum cuspidatum extract and 5-30 parts of red sage root extract.
Further preferably, the raw materials of the traditional Chinese medicine composition are as follows: 9-24 parts of honeysuckle extract, 9-24 parts of radix scrophulariae extract, 5-15 parts of Chinese angelica extract, 5-15 parts of licorice extract, 9-24 parts of fructus forsythiae extract, 9-24 parts of cassia twig extract, 5-15 parts of polygonum cuspidatum extract and 9-24 parts of red sage root extract.
Still more preferably, the raw materials of the traditional Chinese medicine composition are: 12-18 parts of honeysuckle extract, 12-18 parts of radix scrophulariae extract, 7-12 parts of Chinese angelica extract, 7-12 parts of licorice extract, 12-18 parts of fructus forsythiae extract, 12-18 parts of cassia twig extract, 7-12 parts of polygonum cuspidatum extract and 12-18 parts of red sage root extract.
Most preferably, the traditional Chinese medicine composition comprises the following raw materials: 15 parts of honeysuckle extract, 15 parts of radix scrophulariae extract, 9 parts of Chinese angelica extract, 9 parts of liquorice extract, 15 parts of fructus forsythiae extract, 15 parts of cassia twig extract, 9 parts of polygonum cuspidatum extract and 15 parts of red sage root extract.
The extract is water extract or ethanol extract of each raw material medicine respectively.
In the formula of the application, honeysuckle: sweet and cold; the main functions are as follows: clear away heat and toxic materials, disperse wind-heat. Can be used for treating carbuncle, furuncle, pharyngitis, erysipelas, dysentery with blood, wind-heat type common cold, and epidemic febrile disease. Radix scrophulariae: sweet, bitter, salty, slightly cold; the main functions are as follows: clearing heat and cooling blood; nourishing yin to reduce pathogenic fire; detoxify and dissipate nodulation. Can be used for treating heat entering nutrient blood, toxic heat, speckle, heat disease, yin injury, dark red tongue, polydipsia, constipation due to body fluid deficiency, bone steaming, cough, conjunctival congestion, pharyngalgia, diphtheria, scrofula, and carbuncle. Chinese angelica root: sweet, spicy and warm; the main functions are as follows: replenishing blood, promoting blood circulation, regulating menstruation, relieving pain, and loosening bowel to relieve constipation. Can be used for treating sallow complexion due to blood deficiency, dizziness, palpitation, menoxenia, amenorrhea, dysmenorrhea, abdominal pain due to deficiency-cold, rheumatalgia, traumatic injury, carbuncle, skin ulcer, and constipation due to intestinal dryness. Licorice root: sweet and flat; the main functions are as follows: spleen invigorating, qi replenishing, heat and toxic materials clearing away, phlegm eliminating, cough relieving, pain relieving, and medicines regulating. Can be used for treating weakness of spleen and stomach, listlessness, debilitation, palpitation, short breath, cough with excessive phlegm, abdominal pain, limb spasm, carbuncle, swelling, sore and toxic materials, and relieving drug toxicity and intensity. Fructus forsythiae: bitter and slightly cold; the main functions are as follows: clearing away heat and toxic materials, detumescence, resolving hard mass, and dispelling pathogenic wind and heat. Can be used for treating carbuncle, scrofula, acute mastitis, erysipelas, wind-heat type common cold, early stage of warm diseases, damp heat entering nutrient, hyperpyrexia polydipsia, unconsciousness and speckle, and stranguria and pain due to heat. Ramulus Cinnamomi: pungent, sweet and warm; the main functions are as follows: induce sweat to relieve muscle, warm and unblock meridians, strengthen yang and transform qi, calm pulse and reduce qi. Can be used for treating common cold due to wind-cold, abdominal pain, amenorrhea due to blood cold, arthralgia, phlegm retention, edema, palpitation, and dolphin. Giant knotweed rhizome: slightly bitter and slightly cold; the main functions are as follows: promoting diuresis, removing jaundice, clearing heat and detoxicating, removing blood stasis, relieving pain, relieving cough and resolving phlegm. Can be used for treating jaundice due to damp-heat, stranguria with turbid urine, leukorrhagia, rheumatalgia, carbuncle, skin sore, scald due to water and fire, amenorrhea, abdominal mass, traumatic injury, and cough due to lung heat. Root of red-rooted salvia: bitter and slightly cold; the main functions are as follows: promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood and resolving carbuncle. Can be used for treating chest pain, abdominal pain, hypochondriac pain, abdominal mass, pain due to pyretic arthralgia, vexation, insomnia, menoxenia, dysmenorrhea, amenorrhea, and pyocutaneous disease.
In the formula, honeysuckle is a monarch drug, sweet and cold entering the heart and good at clearing heat and detoxicating; fructus forsythiae has effects of clearing heat, removing toxic substances, resolving hard mass, relieving swelling, promoting blood circulation, removing blood stasis, and radix scrophulariae has effects of nourishing yin, reducing pathogenic fire, relieving swelling, and removing toxic substances, and can be used as ministerial drug. Giant knotweed rhizome, rhizoma Polygoni Cuspidati, as an adjuvant drug, has effects of clearing heat, promoting blood circulation and relaxing bowels; licorice root, radix Glycyrrhizae, having the effects of clearing away heat and toxic materials, expelling superficial evils, and ramulus Cinnamomi, having the effects of warming and activating meridians, promoting yang and qi circulation, promoting blood circulation and removing blood stasis, and clearing away heart-fire and relieving restlessness, and cooling blood and resolving carbuncles are all combined as guiding drugs.
As another aspect of the application, the application provides application of the traditional Chinese medicine composition in preparing medicines for treating diseases related to heat-accumulation blood vessels.
The diseases related to the heat-induced blood vessels include, but are not limited to, coronary heart disease, hypertension, peripheral vasculitis, unstable angina, non-ST elevation myocardial infarction, lower limb arteriosclerosis obliterans and viral myocarditis. The application has the beneficial effects that: the traditional Chinese medicine composition is a prescription which is determined to be more effective and can be further developed and converted based on the traditional Chinese medicine clinical theory of syndrome differentiation and treatment and combining the characteristics of new syndrome medicines from clinic and combining the drug effect experimental screening and the new traditional Chinese medicine evaluation requirements. The prescription is used for treating the heat-accumulation blood vessel syndrome, gets rid of the constraint of modern diseases and expands the application range. The research shows that the traditional Chinese medicine composition has good treatment effect on various diseases taking heat-accumulation blood vessels as traditional Chinese medicine symptoms, such as coronary heart disease, hypertension and the like.
Detailed Description
The following describes in detail the examples of the present application, which are implemented on the premise of the technical solution of the present application, and detailed embodiments and specific operation procedures are given, but the scope of protection of the present application is not limited to the following examples.
Example 1
The formula comprises the following components: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: taking the raw materials according to the proportion, adding 10 times of water, soaking for 90 minutes, decocting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into granule.
Example 2
13g of honeysuckle, 17g of radix scrophulariae, 8g of Chinese angelica, 11g of raw liquorice, 13g of fructus forsythiae, 17g of cassia twig, 8g of polygonum cuspidatum and 16g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: taking the raw materials according to the proportion, adding 10 times of water, soaking for 90 minutes, decocting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into capsule.
Example 3
17g of honeysuckle, 13g of radix scrophulariae, 11g of Chinese angelica, 8g of raw liquorice, 17g of fructus forsythiae, 13g of cassia twig, 11g of polygonum cuspidatum and 13g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: taking the raw materials according to the proportion, adding 10 times of water, soaking for 90 minutes, decocting for 30 minutes, and extracting for three times; mixing the extractive solutions, and concentrating to 2.242g crude drug/mL; adding adjuvants into the extract, and making into tablet.
Example 4
14g of honeysuckle, 16g of radix scrophulariae, 7g of angelica sinensis, 10g of raw liquorice, 14g of fructus forsythiae, 16g of cassia twig, 7g of polygonum cuspidatum and 17g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: proportionally taking the raw materials, adding 75% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into granule.
Example 5
16g of honeysuckle, 14g of radix scrophulariae, 10g of Chinese angelica, 7g of raw liquorice, 16g of fructus forsythiae, 14g of cassia twig, 10g of polygonum cuspidatum and 14g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: proportionally taking the raw materials, adding 75% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into capsule.
Example 6
10g of honeysuckle, 22g of radix scrophulariae, 5g of angelica sinensis, 14g of raw liquorice, 10g of fructus forsythiae, 22g of cassia twig, 5g of polygonum cuspidatum and 22g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: proportionally taking the raw materials, adding 75% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into tablet.
Example 7
22g of honeysuckle, 10g of radix scrophulariae, 14g of angelica sinensis, 5g of raw liquorice, 22g of fructus forsythiae, 5g of cassia twig, 14g of polygonum cuspidatum and 10g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: taking the raw materials according to the proportion, pulverizing, adding auxiliary materials and preparing into granules.
Example 8
11g of honeysuckle, 20g of radix scrophulariae, 6g of Chinese angelica, 13g of raw liquorice, 11g of fructus forsythiae, 20g of cassia twig, 6g of polygonum cuspidatum and 20g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: taking the raw materials according to the proportion, pulverizing, adding auxiliary materials and preparing into tablets.
Example 9
20g of honeysuckle, 11g of radix scrophulariae, 13g of Chinese angelica, 6g of raw liquorice, 20g of fructus forsythiae, 6g of cassia twig, 13g of polygonum cuspidatum and 11g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: taking the raw materials according to the proportion, pulverizing, adding auxiliary materials and preparing into capsules.
Example 10
7g of honeysuckle, 28g of radix scrophulariae, 3g of Chinese angelica, 17g of raw liquorice, 7g of fructus forsythiae, 28g of cassia twig, 3g of polygonum cuspidatum and 28g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: proportionally taking the raw materials, adding 50% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into tablet.
Example 11
28g of honeysuckle, 7g of radix scrophulariae, 17g of Chinese angelica, 3g of raw liquorice, 28g of fructus forsythiae, 7g of cassia twig, 17g of polygonum cuspidatum and 6g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: proportionally taking the raw materials, adding 50% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into granule.
Example 12
8g of honeysuckle, 25g of radix scrophulariae, 4g of Chinese angelica, 16g of raw licorice, 8g of fructus forsythiae, 25g of cassia twig, 4g of polygonum cuspidatum and 25g of radix salviae miltiorrhizae;
the preparation method comprises the following steps: proportionally taking the raw materials, adding 50% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into capsule.
Example 13
25g of honeysuckle, 8g of radix scrophulariae, 16g of Chinese angelica, 4g of raw liquorice, 25g of fructus forsythiae, 8g of cassia twig, 16g of polygonum cuspidatum and 8g of radix salviae miltiorrhizae.
The preparation method comprises the following steps: proportionally taking the raw materials, adding 50% ethanol, and reflux-extracting twice; mixing the extractive solutions, volatilizing ethanol, adding adjuvants, and making into dripping pill.
Example 14
The formula comprises the following components: 15g of honeysuckle extract, 15g of radix scrophulariae extract, 9g of Chinese angelica extract, 9g of raw licorice extract, 15g of fructus forsythiae extract, 15g of cassia twig extract, 9g of polygonum cuspidatum extract and 15g of red sage root extract;
the above extracts are water extracts obtained by extracting the raw materials with water respectively.
Example 15
13g of honeysuckle extract, 17g of radix scrophulariae extract, 8g of Chinese angelica extract, 11g of raw licorice extract, 13g of fructus forsythiae extract, 17g of cassia twig extract, 8g of polygonum cuspidatum extract and 16g of red sage root extract;
the above extracts are water extracts obtained by extracting the raw materials with water respectively.
Example 16
17g of honeysuckle extract, 13g of radix scrophulariae extract, 11g of Chinese angelica extract, 8g of raw licorice extract, 17g of fructus forsythiae extract, 13g of cassia twig extract, 11g of polygonum cuspidatum extract and 13g of red sage root extract.
The above extracts are water extracts obtained by extracting the raw materials with water respectively.
Example 17
14g of honeysuckle extract, 16g of radix scrophulariae extract, 7g of Chinese angelica extract, 10g of raw licorice extract, 14g of fructus forsythiae extract, 16g of cassia twig extract, 7g of polygonum cuspidatum extract and 17g of red sage root extract;
the above extracts are water extracts obtained by extracting the raw materials with water respectively.
Example 18
16g of honeysuckle extract, 14g of radix scrophulariae extract, 10g of Chinese angelica extract, 7g of raw licorice extract, 16g of fructus forsythiae extract, 14g of cassia twig extract, 10g of polygonum cuspidatum extract and 14g of red sage root extract.
The above extracts are respectively ethanol extracts obtained by extracting the raw materials with 75% ethanol.
Example 19
10g of honeysuckle extract, 22g of radix scrophulariae extract, 5g of Chinese angelica extract, 14g of raw licorice extract, 10g of fructus forsythiae extract, 22g of cassia twig extract, 5g of polygonum cuspidatum extract and 22g of red sage root extract;
the above extracts are respectively ethanol extracts obtained by extracting the raw materials with 75% ethanol.
Example 20
22g of honeysuckle extract, 10g of radix scrophulariae extract, 14g of Chinese angelica extract, 5g of raw licorice extract, 22g of fructus forsythiae extract, 5g of cassia twig extract, 14g of polygonum cuspidatum extract and 10g of red sage root extract.
The above extracts are respectively ethanol extracts obtained by extracting the raw materials with 75% ethanol.
Example 21
11g of honeysuckle extract, 20g of radix scrophulariae extract, 6g of Chinese angelica extract, 13g of raw licorice extract, 11g of fructus forsythiae extract, 20g of cassia twig extract, 6g of polygonum cuspidatum extract and 20g of red sage root extract;
the above extracts are respectively ethanol extracts obtained by extracting the raw materials with 75% ethanol.
Example 22
20g of honeysuckle extract, 11g of radix scrophulariae extract, 13g of Chinese angelica extract, 6g of raw licorice extract, 20g of fructus forsythiae extract, 6g of cassia twig extract, 13g of polygonum cuspidatum extract and 11g of red sage root extract.
The above extracts are respectively ethanol extracts obtained by extracting the raw materials with 50% ethanol.
Example 23
7g of honeysuckle extract, 28g of radix scrophulariae extract, 3g of Chinese angelica extract, 17g of raw licorice extract, 7g of fructus forsythiae extract, 28g of cassia twig extract, 3g of polygonum cuspidatum extract and 28g of red sage root extract;
the above extracts are respectively ethanol extracts obtained by extracting the raw materials with 50% ethanol.
Example 24
28g of honeysuckle particles, 7g of figwort particles, 17g of angelica particles, 3g of raw licorice particles, 28g of weeping forsythiae capsule particles, 7g of cassia twig particles, 17g of giant knotweed particles and 6g of red sage particles.
The granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw materials with water.
Example 25
8g of honeysuckle particles, 25g of figwort particles, 4g of angelica particles, 16g of raw licorice particles, 8g of weeping forsythiae capsule particles, 25g of cassia twig particles, 4g of giant knotweed particles and 25g of red sage particles;
the granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw materials with water.
Example 26
25g of honeysuckle particles, 8g of figwort particles, 16g of angelica particles, 4g of raw licorice particles, 25g of weeping forsythiae capsule particles, 8g of cassia twig particles, 16g of giant knotweed particles and 8g of red sage particles.
The granules are respectively granules obtained by concentrating, drying and granulating extracts obtained by extracting raw materials with water.
Effect experiment
1 experiment of the antihypertensive Effect of the Chinese medicinal composition on SHR hypertensive rats
1.1 prescription and method for preparing medicine
Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. Adding 10 times of water, soaking for 90 min, extracting for 30 min, and decocting for three times. Mixing the extractive solutions, and concentrating to 2.242g crude drug/mL.
Decoction of four wonderful brave and An Tang: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica and 9g of raw licorice. Adding 10 times of water, soaking for 90 minutes, decocting for 30 minutes, and extracting for three times. Mixing the extractive solutions, and concentrating to 2.242g crude drug/mL.
1.2 grouping of animals and modeling
Male SHR rats 60, 8 weeks old, weighing 180-200g, purchased from Peking Vitre Lihua laboratory animal technologies Co., ltd (certification number: SCXK 2016-0006). Animal houses of basic theory of traditional Chinese medicine research institute of Chinese medical science, 5 animals/cage are fed with mixed formula feed (from Australian feed Co., ltd. In Beijing) and drink water freely.
After 3 days of adaptive feeding, SHR rats were randomly divided into high dose groups, medium dose groups, low dose groups, four wonderful warrior Shang Zu, atorvastatin positive drug control groups and model groups by a random number table method. Alternatively 10 WKY rats were used as normal control group. The high, medium and low dose groups were dosed at 10, 5 and 2.5 times the daily dose of 70 kg of adult human body weight. The control and model groups were given the same volume of distilled water. The stomach infusion amount was 20mL/kg body weight. Blood pressure was measured in the tail vein of each group after 4 weeks.
Animals in the high dose group were dosed at 10 times the clinically equivalent dose (2.242 g crude drug/mL, 0.2mL/10g body weight);
animals in the medium dose group were dosed at 5-fold clinical equivalent dose (1.121 g crude drug/mL, 0.2mL/10g body weight);
the animals in the low dose group were dosed at 2.5 times the clinically equivalent dose (0.560 g crude drug/mL, 0.2mL/10g body weight);
the animals of the positive drug group were perfused with atorvastatin (135 mg in water to 50ml for dissolution).
1.3 experimental results
The results are shown in Table 1.
TABLE 1 blood pressure levels of animals of each group [ (]n＝10)
Note that: ". Times" indicates that the model group compared to the control group has a P < 0.05; " △ "means that the P < 0.05 was compared to the model group.
The results suggest that atorvastatin and low dose groups would be effective in lowering SHR hypertensive rat blood pressure.
2 influence of the Chinese medicinal composition on the animal model of chronic myocardial ischemia
2.1 prescription and preparation method of medicine
Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. Adding 10 times of water, soaking for 90 minutes, decocting for 30 minutes, and extracting for three times. Mixing the extractive solutions, and concentrating to 2.242g crude drug/mL.
2.2 grouping of animals and modeling
Experimental animals were purchased from beijing velarihua experimental animals company. Clean grade, body mass (20.+ -.2) g,8 week C57BL/6J and ApoE-/-mice were selected. 10C 57BL/6J mice were fed normal feed for 6 weeks as a normal control group. 50 ApoE-/-mice were divided into a model group, a high dose group, a medium dose group, a low dose group and a positive drug group, 10 animals per group were fed with high-fat feed for 6 weeks, and subcutaneous injection of isoprenaline (10 mg/kg) was performed at an amount of 0.02mL/g every day 7d before the mice were sacrificed, and an equivalent amount of physiological saline was administered to the blank group. Animal body weight was recorded weekly. 6 hours after the last isoprenaline injection, the animal was examined for animal heart function using a small animal ultrasonic imager.
Animals in the high dose group were dosed at 10 times the clinically equivalent dose (2.242 g crude drug/mL, 0.2mL/10g body weight);
animals in the medium dose group were dosed at 5-fold clinical equivalent dose (1.121 g crude drug/mL, 0.2mL/10g body weight)
Animals in the low dose group were dosed at 2.5 times the clinically equivalent dose (0.560 g crude drug/mL, 0.2mL/10g body weight)
The animals of the positive drug group were perfused with atorvastatin (135 mg in water to 50ml for dissolution).
2.3 experimental results
The results are shown in tables 2 and 3.
TABLE 2 detection results of animal cardiac function indicators of each groupn＝10)
Note that: ". Times" indicates that the model group compared to the control group has a P < 0.05;
IVSd (end diastole compartment thickness), IVSs (end systole compartment thickness), LVPWd (end diastole back wall thickness), LVPWs (end systole back wall thickness), EF (ejection fraction), HR (heart rate).
TABLE 3 detection results of animal cardiac function indicators of each groupn＝10)
Note that: ". Times" indicates that the model group compared to the control group has a P < 0.05;
LVIDd (end diastole left ventricular inner diameter), LVIDs (end systole left ventricular inner diameter), LVVold (end diastole left ventricular volume), LVVols (end systole left ventricular volume), FS (short axis foreshortening), LVm (ventricular mass), LV Mass Corrected (corrected left ventricular mass index).
Research results show that the traditional Chinese medicine composition can obviously improve the heart function of the mice suffering from chronic myocardial ischemia.
3 clinical medical records
Some women, 56 years old, complain about chest needle-like pain, chest distress, aggravate for 1 week, visit before 3 months and 15 days in 2020: patients complain of unsmooth chest before and after the present spring festival, have fast heart rate, stab near 3d chest, and chest distress complicated with systemic debilitation and constipation, and are diagnosed with coronary heart disease by coronary artery CT angiography (CTA) in a certain hospital. The traditional Chinese medicine is used for diagnosing chest stuffiness and pain, dark red tongue with yellow and greasy coating and smooth and rapid pulse, and meets the diagnosis standard of the heat-accumulation blood pulse syndrome of coronary heart disease. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. Re-diagnosis in 2020, 4 months and 18 days: chest pain and chest distress are relieved, chest distress and hypodynamia are caused at night, night sweat is caused, stool is soft, and bitter taste is caused every day. A dark tongue with white and greasy coating and a slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. Three diagnoses in 2020, 5 months and 21 days: the heart beat is increased (110-120 times/min) from the near 1 week, chest distress, dizziness and hypodynamia are frequent at night, the stool is thin after taking the medicine, one row of the medicine is taken every day, no mouth is dry and bitter, and chest pain disappears. A dark tongue with yellow and greasy coating and a deep, slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. The disease is stable and no recurrence occurs after the follow-up half a year.
Some of these men, 60 years old, complain about chest pain, occasionally get a seizure during sleep, start to get a seizure frequently before 1 week, visit before 20 days 7 in 2020: chest distress and dysphoria occur before and after one month of patient complain, chest pricking pain occurs after slight exercise, and unstable angina is confirmed by electrocardiographic examination in a certain hospital along with whole body hypodynamia, shortness of breath and constipation. The traditional Chinese medicine is used for diagnosing chest stuffiness and pain, dry and bitter mouth, red tongue with yellow and greasy coating and smooth and rapid pulse, and meets the diagnosis standard of unstable angina pectoris heat-accumulation blood pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. Re-diagnosis 8 months and 15 days 2020: chest pain and chest distress are relieved, spontaneous perspiration is accompanied, and the stool is softer, and bitter taste is achieved in one line each day. A dark tongue with white and greasy coating and a slippery and rapid pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. Three diagnoses in 2020, 9 months and 20 days: the patient can feel thin after taking the medicine from the stool, and has the symptoms of one line of qi deficiency, debilitation, no dry mouth, bitter taste, slight chest distress, dysphoria and chest pain. The tongue has ecchymosis and ecchymosis points, yellow and greasy tongue coating and slippery pulse. Prescription: 15g of honeysuckle, 15g of radix scrophulariae, 9g of Chinese angelica, 9g of raw liquorice, 15g of fructus forsythiae, 15g of cassia twig, 9g of polygonum cuspidatum and 15g of radix salviae miltiorrhizae. 14 doses of the Chinese medicinal composition are decocted in water for oral administration. The disease is stable and no recurrence occurs after the follow-up half a year.
Claims (9)
1. The application of the traditional Chinese medicine composition in preparing the medicine for treating the coronary heart disease is characterized in that the raw material medicines of the traditional Chinese medicine composition are as follows: 5-30 parts of honeysuckle, 5-30 parts of radix scrophulariae, 3-18 parts of angelica sinensis, 3-18 parts of liquorice, 5-30 parts of fructus forsythiae, 5-30 parts of cassia twig, 3-18 parts of polygonum cuspidatum and 5-30 parts of radix salviae miltiorrhizae.
2. The use according to claim 1, wherein the crude drugs of the traditional Chinese medicine composition are: 9-24 parts of honeysuckle, 9-24 parts of radix scrophulariae, 5-15 parts of angelica sinensis, 5-15 parts of liquorice, 9-24 parts of fructus forsythiae, 9-24 parts of cassia twig, 5-15 parts of polygonum cuspidatum and 9-24 parts of radix salviae miltiorrhizae.
3. The use according to claim 2, wherein the crude drugs of the traditional Chinese medicine composition are: 12-18 parts of honeysuckle, 12-18 parts of radix scrophulariae, 7-12 parts of angelica sinensis, 7-12 parts of liquorice, 12-18 parts of fructus forsythiae, 12-18 parts of cassia twig, 7-12 parts of polygonum cuspidatum and 12-18 parts of radix salviae miltiorrhizae.
4. The use according to claim 3, wherein the crude drugs of the traditional Chinese medicine composition are: 15 parts of honeysuckle, 15 parts of radix scrophulariae, 9 parts of angelica sinensis, 9 parts of liquorice, 15 parts of fructus forsythiae, 15 parts of cassia twig, 9 parts of polygonum cuspidatum and 15 parts of radix salviae miltiorrhizae;
or 13 parts of honeysuckle, 17 parts of radix scrophulariae, 8 parts of angelica sinensis, 11 parts of liquorice, 13 parts of fructus forsythiae, 17 parts of cassia twig, 8 parts of polygonum cuspidatum and 16 parts of radix salviae miltiorrhizae;
or 17 parts of honeysuckle, 13 parts of radix scrophulariae, 11 parts of angelica sinensis, 8 parts of liquorice, 17 parts of fructus forsythiae, 13 parts of cassia twig, 11 parts of polygonum cuspidatum and 13 parts of radix salviae miltiorrhizae.
5. The use according to any one of claims 1 to 4, wherein the Chinese medicinal composition is: the raw materials are respectively crushed and then mixed to form a composition; or, the composition is obtained by crushing the mixed raw materials; or mixing the above raw materials, extracting by conventional extraction method to obtain extract, purifying to obtain effective components, and preparing into conventional oral dosage form by conventional preparation process.
6. The use according to claim 5, wherein said conventional oral dosage form comprises a tablet, capsule, granule, pill, powder, oral liquid.
7. The application of a traditional Chinese medicine composition in preparing a medicine for treating coronary heart disease is characterized in that the traditional Chinese medicine composition comprises the following raw materials: 5-30 parts of honeysuckle extract, 5-30 parts of radix scrophulariae extract, 3-18 parts of Chinese angelica extract, 3-18 parts of licorice extract, 5-30 parts of fructus forsythiae extract, 5-30 parts of cassia twig extract, 3-18 parts of polygonum cuspidatum extract and 5-30 parts of red sage root extract;
wherein the extract is water extract or ethanol extract of each raw material medicine respectively.
8. The use according to claim 7, wherein the raw materials of the traditional Chinese medicine composition are: 9-24 parts of honeysuckle extract, 9-24 parts of radix scrophulariae extract, 5-15 parts of Chinese angelica extract, 5-15 parts of licorice extract, 9-24 parts of fructus forsythiae extract, 9-24 parts of cassia twig extract, 5-15 parts of polygonum cuspidatum extract and 9-24 parts of red sage root extract.
9. The use according to claim 8, wherein the raw materials of the traditional Chinese medicine composition are: 15 parts of honeysuckle extract, 15 parts of radix scrophulariae extract, 9 parts of Chinese angelica extract, 9 parts of liquorice extract, 15 parts of fructus forsythiae extract, 15 parts of cassia twig extract, 9 parts of polygonum cuspidatum extract and 15 parts of red sage root extract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021108976549 | 2021-08-05 | ||
| CN202110897654 | 2021-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115337347A CN115337347A (en) | 2022-11-15 |
| CN115337347B true CN115337347B (en) | 2023-10-24 |
Family
ID=83950784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210933894.4A Active CN115337347B (en) | 2021-08-05 | 2022-08-04 | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115337347B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117797214A (en) * | 2023-12-29 | 2024-04-02 | 中国中医药科技发展中心(国家中医药管理局人才交流中心) | A kind of traditional Chinese medicine composition, its preparation method and application |
| CN117838775A (en) * | 2024-01-09 | 2024-04-09 | 中国中医药科技发展中心(国家中医药管理局人才交流中心) | Application of traditional Chinese medicine composition in preparation of medicine for treating atherosclerosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824020A (en) * | 2005-12-14 | 2006-08-30 | 延边大学 | Medicine for treating coronary heart disease and preparation method thereof |
| CN104826033A (en) * | 2015-06-01 | 2015-08-12 | 青岛友诚高新技术有限公司 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
| CN106606592A (en) * | 2015-10-21 | 2017-05-03 | 肖忠剑 | Traditional Chinese medicine composition for treating coronary heart disease |
-
2022
- 2022-08-04 CN CN202210933894.4A patent/CN115337347B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824020A (en) * | 2005-12-14 | 2006-08-30 | 延边大学 | Medicine for treating coronary heart disease and preparation method thereof |
| CN104826033A (en) * | 2015-06-01 | 2015-08-12 | 青岛友诚高新技术有限公司 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
| CN106606592A (en) * | 2015-10-21 | 2017-05-03 | 肖忠剑 | Traditional Chinese medicine composition for treating coronary heart disease |
Non-Patent Citations (2)
| Title |
|---|
| "热结血脉"概论;胡镜清;;世界科学技术-中医药现代化;21(10);第2005-2008页 * |
| 冠心病"热化"病机辨治探微;李子贇等;世界科学技术-中医药现代化;21(10);第2009-2012页第3节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115337347A (en) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN115337347B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN115337348B (en) | Traditional Chinese medicine composition for treating heat-accumulation blood vessels | |
| CN107648468B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof | |
| CN115227757B (en) | Application of traditional Chinese medicine composition in preparation of antihypertensive drugs | |
| JP2943247B2 (en) | Hypnosis / Sedative | |
| CN103157062B (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN103610795A (en) | Method for preparing eucommia ulmoides step-down oral preparation | |
| CN104435669B (en) | The Chinese medicine composition of the concurrent multiple organ dysfunction syndrome for the treatment of septic shock | |
| CN110292607B (en) | Traditional Chinese medicine composition and preparation method for treating hypertension complicated with left ventricular hypertrophy | |
| CN103768129B (en) | Drug composition for preventing or treating hypertension | |
| CN102526631A (en) | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method | |
| CN100431594C (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN102727766A (en) | Traditional Chinese medicinal preparation for treating comprehensive hemorrhoids, and preparation method thereof | |
| CN117180379B (en) | Traditional Chinese medicine composition for treating qi deficiency and toxin stagnation type hashimoto thyroiditis and application thereof | |
| CN120168581B (en) | A traditional Chinese medicine preparation for nourishing kidney, clearing heat, promoting dampness and removing blood stasis and its application | |
| TW202009011A (en) | Composition for nourishing yin and tonifying kidney and preparation method and applications thereof | |
| CN106729101B (en) | Traditional Chinese medicine composition for treating posterior circulation ischemic stroke and preparation method thereof | |
| KR20190059531A (en) | A chinese medicine for treating fatty liver and its preparation method | |
| CN118924812A (en) | A Chinese medicine composition for improving or treating dilated cardiomyopathy and its application | |
| CN119326847A (en) | A Chinese medicine combination for preventing and treating ischemic heart failure, and its preparation method and application | |
| CN104491454A (en) | Traditional Chinese medicine for treating dizziness due to hyperactivity of liver-yang and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231121 Address after: 712000 No.1, hancang South Road, high tech Industrial Development Zone, Qindu District, Xianyang City, Shaanxi Province Patentee after: SHAANXI MOMENTUM QIXUEHE PHARMACEUTICAL CO.,LTD. Address before: Room 217, No. 55, Xingfu First Village, Chaoyang District, Beijing 100700 Patentee before: China Science and Technology Development Center of Traditional Chinese Medicine (Talent Exchange Center of the State Administration of Traditional Chinese Medicine) |